1. Key Insights

2. Report Introduction

3. Executive Summary of Catheter-related Bloodstream infection (CRBSI)

4. Key Events

5. Epidemiology and Market Forecast Methodology

6. Catheter-related Bloodstream Infection Overview at Glance

6.1. Market Share (%) Distribution of Catheter-related Bloodstream Infection by Therapies in 2023

6.2. Market Share (%) Distribution of Catheter-related Bloodstream Infection by Therapies in 2032

7. Catheter-Related Blood Stream Infections: Disease Background and Overview

7.1. Introduction

7.2. Difference between Central line-associated bloodstream infections and Catheter-related bloodstream infection

7.3. Causes of Catheter-related bloodstream infection

7.4. Micro-organisms

7.4.1. Intravascular Devices

7.4.2. Risk Factor Associated with Catheter-related bloodstream infection

7.4.3. Pathogenesis of Catheter-related bloodstream infection

7.5. Diagnosis of Catheter-related bloodstream infection

7.6. Diagnosis Guidelines Catheter-related bloodstream infection

8. Treatment and Management

8.1. Treatment Guidelines

9. Epidemiology and Patient Population

9.1. Key Findings

9.2. Assumptions and Rationale

9.3. Total Incident Population of Catheter-related bloodstream infection in the 7MM

9.4. United States

9.4.1. Total Incident Population of Catheter-related bloodstream infection in the United States

9.4.2. Total Diagnosed Incident Population of Catheter-related bloodstream infection in the United States

9.4.3. Diagnosed Incident Population of Catheter-related bloodstream infection by Causative Pathogens in the United States

9.5. EU4 and the UK

9.5.1. Total Incident Population of Catheter-related bloodstream infection in EU4 and the UK

9.5.2. Total Diagnosed Incident Population of Catheter-related bloodstream infection in EU4 and the UK

9.5.3. Diagnosed Incident Population of Catheter-related bloodstream Infection by Causative Pathogens in EU4 and the UK

9.6. Japan

9.6.1. Total Incident Population of Catheter-related bloodstream infection in Japan

9.6.2. Total Diagnosed Incident Population of Catheter-related bloodstream infection in Japan

9.6.3. Diagnosed Incident Population of Catheter-related bloodstream Infection by Causative Pathogens in Japan

10. Patient Journey

11. Marketed Products

11.1. DEFENCATH: CorMedix

11.1.1. Product Description

11.1.2. Mechanism of Action

11.1.3. Regulatory milestones

11.1.4. Clinical Development

11.1.4.1. Clinical Trials Information

11.1.5. Safety and Efficacy

11.1.6. Product Profile

12. Emerging Therapies

12.1. MINO-LOK: Citius Pharmaceuticals

12.1.1. Product Description

12.1.2. Other Developmental Activities

12.1.3. Clinical Development

12.1.4. Product Profile

13. Catheter-related bloodstream infection: 7 Major Market Analysis

13.1. Key Findings

13.2. Market Outlook

13.3. Conjoint Analysis

13.4. Key Market Forecast Assumptions

13.5. Total Market Size of Catheter-related bloodstream infection in the 7MM

13.6. United States

13.6.1. Total Market Size of Catheter-related bloodstream infection in the United States

13.6.2. Market Size of Catheter-related bloodstream infection by Therapies in the United States

13.7. EU4 and the UK

13.7.1. Total Market size of Catheter-related bloodstream infection in EU4 and the UK

13.7.2. Market Size of Catheter-related bloodstream infection by Therapies in EU4 and the UK

13.8. Japan

13.8.1. Total Market size of Catheter-related bloodstream infection in Japan

13.8.2. Market Size of Catheter-related bloodstream infection by Therapies in Japan

14. Unmet Needs

15. SWOT Analysis

16. KOL Views

17. Market Access and Reimbursement

18. Appendix

18.1. Bibliography

18.3. Report Methodology

19. DRACapabilities

20. Disclaimer

21. About DRA